

China approves first and only Remote Electrical Neuromodulation based migraine treatment

03 October 2025 | News

Migraine is a significant public health concern in China, with an estimated 130 million people affected



Pier 88 Health, a digital health company dedicated to reshaping chronic pain management and bringing breakthrough global medical innovations to Greater China, and Israel-based Theranica, a prescribed digital therapeutics company, have announced that the Nerivio® REN wearable, a novel treatment of migraine, has received regulatory approval from China's National Medical Products Administration (NMPA).

The registration certificate marks the first and only approval in China of a wearable migraine device using the Remote Electrical Neuromodulation (REN) technology. This drug-free, smartphone-controlled prescribed therapy provides a clinically validated, self-administered solution for people living with migraine.

By offering an earlier, non-pharmacological intervention, the REN wearable may help prevent disease progression and reduce the risk of migraine chronification, a key driver of long-term disability.

Migraine is a significant public health concern in China, with an estimated 130 million people affected, yet limited access to specialized care and heavy reliance on oral medications present substantial barriers for patients and healthcare providers. If left undertreated, episodic migraine often progresses to chronic migraine, further increasing disability and healthcare costs. The demand for drug-free, non-invasive therapies is growing, particularly among younger and working-age populations. The REN wearable's entry into the market is well-aligned with China's shift toward digital health innovation and patient-empowered solutions.